Free Trial
NASDAQ:VRAX

Virax Biolabs Group Q4 2026 Earnings Report

Virax Biolabs Group logo
$2.40 +0.20 (+9.09%)
Closing price 04:00 PM Eastern
Extended Trading
$2.32 -0.09 (-3.54%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Virax Biolabs Group EPS Results

Actual EPS
-$0.20
Consensus EPS
-$1.75
Beat/Miss
Beat by +$1.56
One Year Ago EPS
N/A

Virax Biolabs Group Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.00 million
Beat/Miss
Beat by +$4.41 thousand
YoY Revenue Growth
N/A

Virax Biolabs Group Announcement Details

Quarter
Q4 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Virax Biolabs Group's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Virax Biolabs Group Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Virax Biolabs Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Virax Biolabs Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Virax Biolabs Group and other key companies, straight to your email.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ:VRAX) is a biotechnology company focused on the prevention, detection and diagnosis of viral diseases. The company develops and commercializes diagnostic technologies intended to help identify infections and assess immune responses to viral pathogens.

Its portfolio includes molecular diagnostic products and immune-profiling technologies designed to measure T-cell responses to specific viruses. These products are intended for use by healthcare providers, laboratories and other organizations involved in infectious-disease testing and monitoring.

Virax Biolabs is headquartered in the United Kingdom and has pursued international commercialization and distribution opportunities for its diagnostic products. The company became publicly traded on the Nasdaq under the symbol VRAX in 2022. James Foster has served as the company’s chief executive officer and chairman.

View Virax Biolabs Group Profile